LIVIVO - Search results -

Search results

Result 1 - 10 of total 48

Search options

Article ; Online: Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It.

Migliorisi, Giulia / Vella, Giovanna / Dal Buono, Arianna / Gabbiadini, Roberto / Busacca, Anita / Loy, Laura / Bezzio, Cristina / Vinciguerra, Paolo / Armuzzi, Alessandro

Cells

2024 Volume 13, Issue 2

Abstract: Background and aims: Inflammatory bowel diseases (IBD) are multifactorial chronic inflammatory disorders affecting the gastrointestinal tract. However, a broad spectrum of extraintestinal manifestations (EIMs) is associated with IBD, affecting several ... ...

Abstract	Background and aims: Inflammatory bowel diseases (IBD) are multifactorial chronic inflammatory disorders affecting the gastrointestinal tract. However, a broad spectrum of extraintestinal manifestations (EIMs) is associated with IBD, affecting several organs and systems, such as the skin, musculoskeletal and hepatobiliary systems, and, not least, the eye. Approximately 10% of IBD patients can develop ocular EIMs (O-EIMs) with a higher prevalence in Crohn's disease (CD). Eye-redness, photophobia, pain, and blurred vision are the common symptoms, with a wide rate of severity and clinical impact on the quality of life. This narrative review aims to summarize the prevalence, pathogenesis, and current evidence-based management of O-EIMs, underlying the importance of a holistic approach and specialties collaboration for a prompt diagnosis and treatment. Methods: PubMed was searched up to December 2023 to identify relevant studies investigating the pathogenesis, epidemiology, and treatment of O-EIMs in IBD patients. Results: The mechanisms underlying O-EIMs are partially unknown, encompassing immune dysregulation, shared antigens between the eye and the gut, genetic predisposition, and systemic inflammation driven by high levels of interleukins and cytokines in IBD patients. The complexity of O-EIMs' pathogenesis reflects in the management of these conditions, varying from topical and systemic steroids to immunomodulatory molecules and biologic therapy, such as anti-tumor necrosis factor (TNF)-alpha. A multidisciplinary approach is the backbone of the management of O-EIMs.
MeSH term(s)	Humans ; Quality of Life ; Eye ; Face ; Inflammatory Bowel Diseases ; Crohn Disease
Language	English
Publishing date	2024-01-12
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2661518-6
ISSN	2073-4409 ; 2073-4409
ISSN (online)	2073-4409
ISSN	2073-4409
DOI	10.3390/cells13020142
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Cytokines in Spondyloarthritis and Inflammatory Bowel Diseases: From Pathogenesis to Therapeutic Implications.

Felice, Carla / Dal Buono, Arianna / Gabbiadini, Roberto / Rattazzi, Marcello / Armuzzi, Alessandro

International journal of molecular sciences

2023 Volume 24, Issue 4

Abstract: Spondyloarthritis and inflammatory bowel diseases are chronic immune disorders of the joints and the gut that often coexist in the same patient, increasing the burden of each disorder, worsening patients' quality of life, and influencing therapeutic ... ...

Abstract	Spondyloarthritis and inflammatory bowel diseases are chronic immune disorders of the joints and the gut that often coexist in the same patient, increasing the burden of each disorder, worsening patients' quality of life, and influencing therapeutic strategies. Genetic predisposition, environmental triggers, microbiome features, immune cell trafficking, and soluble factors such as cytokines contribute to the pathogenesis of both articular and intestinal inflammation. Most of the molecular targeted biological therapies developed over the last two decades were based on evidence that specific cytokines may be involved in these immune diseases. Despite pro-inflammatory cytokine pathways sharing the pathogenesis of both articular and gut diseases (i.e., tumor necrosis factor and interleukin-23), several other cytokines (i.e., interleukin-17) may be differently involved in the tissue damage process, depending on the specific disease and the organ involved in inflammation, making difficult the identification of a therapeutic plan that is efficacious for both inflammatory manifestations. In this narrative review, we comprehensively summarize the current knowledge on cytokine involvement in spondyloarthritis and inflammatory bowel diseases, underlining similarities and differences among their pathogenetic pathways; finally, we provide an overview of current and potential future treatment strategies to simultaneously target both articular and gut immune disorders.
MeSH term(s)	Humans ; Cytokines/metabolism ; Inflammatory Bowel Diseases/metabolism ; Quality of Life ; Spondylarthritis/metabolism
Chemical Substances	Cytokines
Language	English
Publishing date	2023-02-16
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms24043957
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: to the

Gabbiadini, Roberto / Dal Buono, Arianna / Mastrorocco, Elisabetta / Solitano, Virginia / Repici, Alessandro / Spinelli, Antonino / Condorelli, Gianluigi / Armuzzi, Alessandro

Frontiers in cardiovascular medicine

2023 Volume 10, Page(s) 1143293

Abstract: Atherosclerotic cardiovascular disease and stroke are the leading causes of morbidity and mortality worldwide. Along to the traditional risk factors for these diseases, chronic inflammation is known to be an important player in accelerating the process ... ...

Abstract	Atherosclerotic cardiovascular disease and stroke are the leading causes of morbidity and mortality worldwide. Along to the traditional risk factors for these diseases, chronic inflammation is known to be an important player in accelerating the process of atherosclerosis, which can result in an increased incidence of arterial thromboembolic events. As in other chronic inflammatory diseases, in the past few years, several studies suggested that subjects affected by inflammatory bowel diseases (IBD) may also be at an incremented risk of atherosclerotic disease, especially during the periods of disease's flare. Therefore, IBD treatment may assume an important role for achieving both disease remission and the control of the atherosclerotic risk. In this article we aimed to perform a comprehensive review on evidence on the increased risk of arterial thromboembolic events in patients affected by IBD and discuss the potential role of IBD therapy in reducing this risk.
Language	English
Publishing date	2023-05-16
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2781496-8
ISSN	2297-055X
ISSN	2297-055X
DOI	10.3389/fcvm.2023.1143293
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management.

Terrin, Maria / Migliorisi, Giulia / Dal Buono, Arianna / Gabbiadini, Roberto / Mastrorocco, Elisabetta / Quadarella, Alessandro / Repici, Alessandro / Santoro, Armando / Armuzzi, Alessandro

International journal of molecular sciences

2023 Volume 24, Issue 14

Abstract: The advent of immunotherapy, specifically of immune checkpoint inhibitors (ICIs), for the treatment of solid tumors has deeply transformed therapeutic algorithms in medical oncology. Approximately one-third of patients treated with ICIs may de velop ... ...

Abstract	The advent of immunotherapy, specifically of immune checkpoint inhibitors (ICIs), for the treatment of solid tumors has deeply transformed therapeutic algorithms in medical oncology. Approximately one-third of patients treated with ICIs may de velop immune-related adverse events, and the gastrointestinal tract is often affected by different grades of mucosal inflammation. Checkpoint inhibitors colitis (CIC) presents with watery or bloody diarrhea and, in the case of severe symptoms, requires ICIs discontinuation. The pathogenesis of CIC is multifactorial and still partially unknown: anti-tumor activity that collaterally effects the colonic tissue and the upregulation of specific systemic inflammatory pathways (i.e., CD8+ cytotoxic and CD4+ T lymphocytes) are mainly involved. Many questions remain regarding treatment timing and options, and biological treatment, especially with anti-TNF alpha, can be offered to these patients with the aim of rapidly resuming oncological therapies. CIC shares similar pathogenesis and aspects with inflammatory bowel disease (IBD) and the use of ICI in IBD patients is under evaluation. This review aims to summarize the pathogenetic mechanism underlying CIC and to discuss the current evidenced-based management options, including the role of biological therapy, emphasizing the relevant clinical impact on CIC and the need for prompt recognition and treatment.
MeSH term(s)	Humans ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Colitis/chemically induced ; Colitis/therapy ; Inflammatory Bowel Diseases/drug therapy ; Inflammatory Bowel Diseases/etiology ; Neoplasms/drug therapy
Chemical Substances	Tumor Necrosis Factor Inhibitors
Language	English
Publishing date	2023-07-15
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms241411504
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Fibro-Stenosing Crohn's Disease: What Is New and What Is Next?

Solitano, Virginia / Dal Buono, Arianna / Gabbiadini, Roberto / Wozny, Marek / Repici, Alessandro / Spinelli, Antonino / Vetrano, Stefania / Armuzzi, Alessandro

Journal of clinical medicine

2023 Volume 12, Issue 9

Abstract: Fibro-stenosing Crohn's disease (CD) is a common disease presentation that leads to impaired quality of life and often requires endoscopic treatments or surgery. From a pathobiology perspective, the conventional view that intestinal fibro-stenosis is an ... ...

Abstract	Fibro-stenosing Crohn's disease (CD) is a common disease presentation that leads to impaired quality of life and often requires endoscopic treatments or surgery. From a pathobiology perspective, the conventional view that intestinal fibro-stenosis is an irreversible condition has been disproved. Currently, there are no existing imaging techniques that can accurately quantify the amount of fibrosis within a stricture, and managing patients is challenging, requiring a multidisciplinary team. Novel therapies targeting different molecular components of the fibrotic pathways are increasing regarding other diseases outside the gut. However, a large gap between clinical need and the lack of anti-fibrotic agents in CD remains. This paper reviews the current state of pathobiology behind fibro-stenosing CD, provides an updated diagnostic and therapeutic approach, and finally, focuses on clinical trial endpoints and possible targets of anti-fibrotic therapies.
Language	English
Publishing date	2023-04-22
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm12093052
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Mental Illnesses in Inflammatory Bowel Diseases:

Bartocci, Bianca / Dal Buono, Arianna / Gabbiadini, Roberto / Busacca, Anita / Quadarella, Alessandro / Repici, Alessandro / Mencaglia, Emanuela / Gasparini, Linda / Armuzzi, Alessandro

Medicina (Kaunas, Lithuania)

2023 Volume 59, Issue 4

Abstract: Background and ... ...

Abstract	Background and aims
MeSH term(s)	Male ; Humans ; Female ; Quality of Life/psychology ; Inflammatory Bowel Diseases/complications ; Inflammatory Bowel Diseases/epidemiology ; Comorbidity ; Anxiety/epidemiology ; Cognition Disorders/epidemiology ; Depression/epidemiology
Language	English
Publishing date	2023-03-30
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2188113-3
ISSN	1648-9144 ; 1010-660X
ISSN (online)	1648-9144
ISSN	1010-660X
DOI	10.3390/medicina59040682
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6270: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Management of Post-Operative Crohn's Disease: Knowns and Unknowns.

Spertino, Matteo / Gabbiadini, Roberto / Dal Buono, Arianna / Busacca, Anita / Franchellucci, Gianluca / Migliorisi, Giulia / Repici, Alessandro / Spinelli, Antonino / Bezzio, Cristina / Armuzzi, Alessandro

Journal of clinical medicine

2024 Volume 13, Issue 8

Abstract: Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by relapsing-remission phases. CD often requires surgical intervention during its course, mainly ileo-cecal/ileo-colonic resection. However, surgery in CD ...

Abstract	Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by relapsing-remission phases. CD often requires surgical intervention during its course, mainly ileo-cecal/ileo-colonic resection. However, surgery in CD is not curative and post-operative recurrence (POR) can happen. The management of CD after surgery presents challenges. Ensuring timely, effective, and safe therapy to prevent POR is essential but difficult, considering that approximately 20-30% of subjects may not experience endoscopic POR and that 40-50% will only exhibit intermediate lesions, which carry a low risk of mid- and long-term clinical and surgical POR. Currently, there are two accepted intervention strategies: early post-operative prophylactic therapy (systematically or based on the patient's risk of recurrence) or starting therapy after confirming endoscopic POR 6-12 months after surgery (endoscopy-driven prophylactic therapy). The risk of overtreatment lies in exposing patients to undesired adverse events, along with the costs associated with medications. Conversely, undertreatment may lead to missed opportunities to prevent bowel damage and the necessity for additional surgery. This article aims to perform a comprehensive review regarding the optimal strategy to reduce the risk of POR in CD patients and the current therapeutic options.
Language	English
Publishing date	2024-04-16
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm13082300
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Ileal Pouch–Anal Anastomosis and Pouchitis: The Role of the Microbiota in the Pathogenesis and Therapy

Gabbiadini, Roberto / Dal Buono, Arianna / Correale, Carmen / Spinelli, Antonino / Repici, Alessandro / Armuzzi, Alessandro / Roda, Giulia

Nutrients. 2022 June 24, v. 14, no. 13

2022

Abstract: Inflammatory bowel diseases, Crohn’s disease and ulcerative colitis, are life-long disorders characterized by the chronic relapsing inflammation of the gastrointestinal tract with the intermittent need for escalation treatment and, eventually, even ... ...

Abstract	Inflammatory bowel diseases, Crohn’s disease and ulcerative colitis, are life-long disorders characterized by the chronic relapsing inflammation of the gastrointestinal tract with the intermittent need for escalation treatment and, eventually, even surgery. The total proctocolectomy with ileal pouch–anal anastomosis (IPAA) is the surgical intervention of choice in subjects affected by ulcerative colitis (UC). Although IPAA provides satisfactory functional outcomes, it can be susceptible to some complications, including pouchitis as the most common. Furthermore, 10–20% of the pouchitis may develop into chronic pouchitis. The etiology of pouchitis is mostly unclear. However, the efficacy of antibiotics in pouchitis suggests that the dysbiosis of the IPAA microbiota plays an important role in its pathogenesis. We aimed to review the role of the microbiota in the pathogenesis and as a target therapy in subjects who develop pouchitis after undergoing the surgical intervention of total proctocolectomy with IPAA reconstruction.
Keywords	digestive tract ; dysbiosis ; etiology ; ileum ; inflammation ; microorganisms ; pathogenesis ; surgery ; ulcerative colitis
Language	English
Dates of publication	2022-0624
Publishing place	Multidisciplinary Digital Publishing Institute
Document type	Article
ZDB-ID	2518386-2
ISSN	2072-6643
ISSN	2072-6643
DOI	10.3390/nu14132610
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article: EUS-guided hepaticogastrostomy and antegrade direct peroral cholangioscopy: An effective alternative to overcome the distance (with video).

Fugazza, Alessandro / Gabbiadini, Roberto / Sollai, Mauro / Spadaccini, Marco / Repici, Alessandro / Anderloni, Andrea

Endoscopic ultrasound

2021 Volume 11, Issue 4, Page(s) 327–329

Language	English
Publishing date	2021-11-29
Publishing country	China
Document type	Journal Article
ZDB-ID	2998317-4
ISSN	2226-7190 ; 2303-9027
ISSN (online)	2226-7190
ISSN	2303-9027
DOI	10.4103/EUS-D-21-00087
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy.

Dal Buono, Arianna / Gabbiadini, Roberto / Solitano, Virginia / Vespa, Edoardo / Parigi, Tommaso Lorenzo / Repici, Alessandro / Spinelli, Antonino / Armuzzi, Alessandro

Clinical and experimental gastroenterology

2022 Volume 15, Page(s) 121–128

Abstract: Background and aims: Patients affected by moderate-to-severe Ulcerative Colitis (UC) demand a challenging management. Small molecules, administrated as oral agents, have the ambition of overcoming the limitations of the biologic agents (ie, parenteral ... ...

Abstract	Background and aims: Patients affected by moderate-to-severe Ulcerative Colitis (UC) demand a challenging management. Small molecules, administrated as oral agents, have the ambition of overcoming the limitations of the biologic agents (ie, parenteral administration, rapidity of action, primary and secondary non-responsiveness). Beyond tofacitinib, a pan-Janus kinase (JAK) inhibitor already approved for the treatment of moderate-to-severe UC, novel more selective molecules like filgotinib are being currently evaluated in randomized clinical trials. We aimed to review the current evidence on filgotinib, a JAK-1 preferential inhibitor, in the treatment of UC and its place in therapy in the current scenario. Methods: PubMed and EMBASE were searched to identify relevant studies: those investigating the efficacy and safety of filgotinib in the treatment of UC patients were included in this narrative review. Results: The current preliminary data have shown that filgotinib is safe and effective in inducing clinical end endoscopic response in both biologic-naïve and biologic-experienced patients with moderate-to-severe UC, also with high inflammatory burden at baseline. In the SELECTION trial, one case of pulmonary embolism occurred with filgotinib 200 mg induction, and three venous thrombosis cases were observed in the placebo maintenance/LTE; the incidence of herpes zoster was ≤1% in all UC treated patients. Filgotinib represents an appealing treatment option for its high selectiveness, route of administration and rapidity of action; cost-effectiveness studies and head-to-head trials are needed to better define its place in therapy.
Language	English
Publishing date	2022-07-23
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2520690-4
ISSN	1178-7023
ISSN	1178-7023
DOI	10.2147/CEG.S350193
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito